Eli Lilly and Co (XSWX:LLY) Total Payout Ratio: 0.43 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:LLY Eli Lilly and Co XSWX:LLY
99 GF Score
Price CHF925.00
GF Value CHF1,133.72
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Total Payout Ratio?

Eli Lilly and Co XSWX:LLY -1.60% 99 Total Payout Ratio is 0.43 as of Jul. 16, 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 99/100 and a GF Value™ of CHF1,133.72 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Eli Lilly and Co's current Total Payout Ratio is 0.43.

Eli Lilly and Co Total Payout Ratio Related Terms

Eli Lilly and Co Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Total Payout Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.81 0.92 0.68 0.46

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.36 0.37 0.43 0.53

XSWX:LLY vs JNJ, ABBV, MRK: Total Payout Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co Total Payout Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Total Payout Ratio falls into.


XSWX:LLY
99GF Score
Eli Lilly and Co XSWX:LLY
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Eli Lilly and Co's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-3273.665 + 0 + -4290.51) / 16448.016
=0.46

Eli Lilly and Co's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-1854.879 + 0 + -1218.74) / 5822.871
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.43 mean?
Eli Lilly and Co (XSWX:LLY) has a Total Payout Ratio of 0.43 as of Jul. 16, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Total Payout Ratio too high?
Eli Lilly and Co's current Total Payout Ratio is 0.43. Overall, Eli Lilly and Co has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Total Payout Ratio compare to JNJ and ABBV?
Eli Lilly and Co's Total Payout Ratio of 0.43 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Drug Manufacturers company?
A good Total Payout Ratio depends on the Drug Manufacturers industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Total Payout Ratio is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,133.72, compared to a current price of CHF925.00 — trading 18.4% below its estimated fair value. The current Total Payout Ratio is 0.43. Eli Lilly and Co's overall GF Score™ is 99/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Total Payout Ratio is 0.43 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF925.00 is trading 18.4% below its estimated GF Value™ of CHF1,133.72. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Total Payout Ratio: 0.43
  • GF Value™: CHF1,133.72 vs. price of CHF925.00 (18.4% below fair value)
  • GF Score™: 99/100 with 4 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
99GF Score

Get the complete analysis for XSWX:LLY

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF925.00
Price
CHF1,133.72
GF Value